Iradimed (IRMD) Earning Somewhat Positive Media Coverage, Analysis Shows

News coverage about Iradimed (NASDAQ:IRMD) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.5335908094404 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of NASDAQ:IRMD traded down $0.15 during trading on Friday, hitting $18.60. 19,536 shares of the company’s stock were exchanged, compared to its average volume of 17,847. Iradimed has a 52-week low of $8.25 and a 52-week high of $19.25. The stock has a market capitalization of $198.20 million, a P/E ratio of 232.50 and a beta of 1.40.

Iradimed (NASDAQ:IRMD) last released its earnings results on Monday, April 30th. The medical equipment provider reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.04. Iradimed had a return on equity of 6.27% and a net margin of 6.29%. The firm had revenue of $7.11 million during the quarter, compared to analysts’ expectations of $6.83 million. research analysts predict that Iradimed will post 0.32 EPS for the current year.

Several research firms recently issued reports on IRMD. ValuEngine upgraded Iradimed from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded Iradimed from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Friday, May 4th. Four research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $18.33.

In other Iradimed news, insider Louis S. Waldman sold 5,221 shares of the firm’s stock in a transaction that occurred on Friday, May 4th. The stock was sold at an average price of $18.19, for a total transaction of $94,969.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Francis X. Casey sold 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $18.50, for a total value of $647,500.00. Following the transaction, the vice president now owns 105,831 shares of the company’s stock, valued at approximately $1,957,873.50. The disclosure for this sale can be found here. Insiders have sold 42,120 shares of company stock valued at $776,538 in the last quarter. 61.20% of the stock is currently owned by company insiders.

Iradimed Company Profile

IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name.

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply